Atlas Trials

An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings

Clinical trial NCT06013475 · COMPLETED

Trial details

NCT number
NCT06013475
Sponsor
Bayer
Status
COMPLETED
Study type
OBSERVATIONAL
Non-metastatic Castration-resistant Prostate Cancer
Start date
2023-08-31
Primary completion
2024-06-28
Enrollment
1375

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.